BiotechTube
Mabpro

Mabpro

Bratislava, Europe - Other· Est.
mabpro.sk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MABPRO is a private, European biotech focused on a novel CA IX-targeting immunotherapy platform for hypoxic tumors, including triple-negative breast cancer and renal cell carcinoma. The company integrates therapeutic antibody development with a sophisticated diagnostic and bioinformatics program for patient stratification, aligning with precision medicine. It has gained recognition through the Horizon Europe Seal of Excellence and positive EIC Accelerator evaluations, positioning it in the pre-clinical/early clinical development stage. MABPRO's strategy leverages a network of clinical and academic partners in Central Europe to advance its programs.

Oncology

Technology Platform

Personalized immunotherapy platform targeting Carbonic Anhydrase IX (CA IX) on hypoxic tumors. Combines humanized monoclonal antibodies (CA9hu-1, CA9hu-2) designed for immune recruitment (ADCC) and enzymatic inhibition with a companion diagnostic and patient stratification system using bioinformatics and machine learning.

Opportunities

Large unmet need in aggressive, hypoxic tumors across multiple high-incidence cancers like TNBC and RCC.
The integrated therapy-diagnostic platform aligns perfectly with the growing precision medicine paradigm, potentially enabling faster development and premium pricing.
Recognition from the EU (Seal of Excellence) facilitates non-dilutive grant funding and validation.

Risk Factors

High scientific risk associated with the novel CA IX targeting mechanism and its clinical efficacy.
Intense competition in the oncology immunotherapy space from larger players.
Reliance on grant funding and the challenge of securing later-stage capital to advance through costly clinical trials.

Competitive Landscape

The competitive landscape is broad in immuno-oncology, but focused CA IX targeting is a specialized niche. MABPRO may compete with other companies developing CA IX inhibitors (small molecule or antibody) or broader hypoxia-targeting therapies. Its key differentiator is the combination of immune recruitment, enzymatic inhibition, and a dedicated patient stratification platform.

More companies in Europe - Other →